{"product_id":"cst-3983s","title":"CST,  3983S, Phospho-ALK (Tyr1278\/1282\/1283) Antibody","description":"Polyclonal Antibody for studying ALK (Tyr1278\/Tyr1282\/Tyr1283) phosphate. Validated for Western Blotting,Immunoprecipitation. Available in 2 sizes. Highly specific and rigorously validated in-house, Phospho-ALK (Tyr1278\/1282\/1283) Antibody (CST #3983) is ready to ship.\n\n\u003cb\u003eProduct Usage Information\u003c\/b\u003e\nWestern Blotting: 1:1000\nImmunoprecipitation: 1:50\n\u003cb\u003eStorage\u003c\/b\u003e\nSupplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg\/ml BSA and 50% glycerol. Store at -20°C. Do not aliquot the antibody.\n\u003cb\u003eProtocol\u003c\/b\u003e\nAvailable protocols: Western Blotting, Immunoprecipitation\n\u003cb\u003eSpecificity \/ Sensitivity\u003c\/b\u003e\nPhospho-ALK (Tyr1278\/1282\/1283) Antibody detects ALK only when phosphorylated at Tyr1278\/1282\/1283, which is equivalent to Tyr338\/342\/343 of NPM-ALK. This antibody might also have slight reactivity toward ALK when it is phosphorylated at Tyr1283 alone. This antibody also reacts with leukocyte tyrosine kinase (LTK) phosphorylated at Tyr672\/676\/677.\nSpecies Reactivity: Human\n\u003cb\u003eSource \/ Purification\u003c\/b\u003e\nPolyclonal antibodies are produced by immunizing animals with a synthetic phosphopeptide corresponding to residues surrounding Tyr1278\/1282\/1283 of human ALK protein. Antibodies are purified by protein A and peptide affinity chromatography.\n\u003cb\u003eBackground\u003c\/b\u003e\nAnaplastic lymphoma kinase (ALK) is a tyrosine kinase receptor for pleiotrophin (PTN), a growth factor involved in embryonic brain development (1-3). In ALK-expressing cells, PTN induces phosphorylation of both ALK and the downstream effectors IRS-1, Shc, PLCγ, and PI3 kinase (1). ALK was originally discovered as a nucleophosmin (NPM)-ALK fusion protein produced by a translocation (4). Investigators have found that the NPM-ALK fusion protein is a constitutively active, oncogenic tyrosine kinase associated with anaplastic lymphoma (4). Research literature suggests that activation of PLCγ by NPM-ALK may be a crucial step for its mitogenic activity and involved in the pathogenesis of anaplastic lymphomas (5). A distinct ALK oncogenic fusion protein involving ALK and echinoderm microtubule-associated protein like 4 (EML4) has been described in the research literature from a non-small cell lung cancer (NSCLC) cell line, with corresponding fusion transcripts present in some cases of lung adenocarcinoma. The short, amino-terminal region of the microtubule-associated protein EML4 is fused to the kinase domain of ALK (6-8). Phosphorylation of ALK on Tyr1278\/Tyr1282\/Tyr1283 was identified at Cell Signaling Technology (CST) using PhosphoScan , CST's LC-MS\/MS platform for phosphorylation site discovery. Phosphorylation of ALK at these three sites was observed in select carcinoma cell lines and in tumors (6).\n\u003cb\u003eAlternate Names\u003c\/b\u003e\nALK; ALK receptor tyrosine kinase; ALK tyrosine kinase receptor; Anaplastic lymphoma kinase; anaplastic lymphoma receptor tyrosine kinase; CD246; CD246 antigen; mutant anaplastic lymphoma kinase; NBLST3\n\n\u003cb\u003eSpecification\u003c\/b\u003e\n\nREACTIVITY: H\nSENSITIVITY: Endogenous\nMW (kDa): 80 (NPM-ALK), 220 (ALK)\nSOURCE: Rabbit","brand":"CST","offers":[{"title":"Default Title","offer_id":46799473901737,"sku":"3983S","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/products\/cst-3983s","provider":"Iright","version":"1.0","type":"link"}